COP vs JNJ: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
ConocoPhillips · Energy
$108.44
-21.6% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
COP has more upside to fair value
(-21.6%).
COP trades at a lower forward P/E
(18.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
JNJ |
| Current Price |
$108.44 |
$253.85 |
| Fair Value Estimate |
$85.04 |
$198.76 |
| Upside to Fair Value |
-21.6%
|
-21.7%
|
| Market Cap |
$132.1B |
$611.1B |
| Forward P/E |
18.4x
|
29.3x
|
| EV / EBITDA |
6.1x
|
19.2x
|
| Price / Sales |
2.3x
|
6.3x
|
| Price / FCF |
8.6x
|
34.3x
|
| Revenue Growth YoY |
-2.5%
|
+9.9%
|
| Gross Margin |
29.2%
|
69.1%
|
| Operating Margin |
18.3%
|
26.9%
|
| Return on Equity |
11.3%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.64%
|
2.91%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
ConocoPhillips is a major player in the Energy sector focused on Oil & Gas Exploration & Production. The company demonstrates medium business quality with a stable competitive position but faces earnings pressure as reflected in a 23.4% decline in earnings and a 2.5% decline in revenue in the most recent quarter year-over-year. Despite a solid ROE of 11.3% and attractive margins (gross margin 29.…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
COP |
JNJ |
| Zone Low |
$63.78 |
$149.07 |
| Zone High |
$72.28 |
$168.95 |
| In Buy Zone? |
No
|
No
|